1. |
Ong AC, Devuyst O, Knebelmann B, et al. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet, 2015, 385(9981): 1993-2002.
|
2. |
Aapkes SE, Bernts LHP, Barten TRM, et al. Estrogens in polycystic liver disease: a target for future therapies? Liver Int, 2021, 41(9): 2009-2019.
|
3. |
Bergmann C, Guay-Woodford LM, Harris PC, et al. Polycystic kidney disease. Nat Rev Dis Primers, 2018, 4(1): 50. doi: 10.1038/s41572-018-0047-y.
|
4. |
Cornec-Le Gall E, Torres VE, Harris PC. Genetic complexity of autosomal dominant polycystic kidney and liver diseases. J Am Soc Nephrol, 2018, 29(1): 13-23.
|
5. |
Senum SR, Li YSM, Benson KA, et al. Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. Am J Hum Genet, 2022, 109(1): 136-156.
|
6. |
Pisani I, Allinovi M, Palazzo V, et al. More dissimilarities than affinities between DNAJB11-PKD and ADPKD. Clin Kidney J, 2022, 15(6): 1179-1187.
|
7. |
Besse W, Dong K, Choi J, et al. Isolated polycystic liver disease genes define effectors of polycystin-1 function. J Clin Invest, 2017, 127(5): 1772-1785.
|
8. |
Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet, 2019, 393(10174): 919-935.
|
9. |
van Aerts RMM, van de Laarschot LFM, Banales JM, et al. Clinical management of polycystic liver disease. J Hepatol, 2018, 68(4): 827-837.
|
10. |
Perugorria MJ, Masyuk TV, Marin JJ, et al. Polycystic liver diseases: advanced insights into the molecular mechanisms. Nat Rev Gastroenterol Hepatol, 2014, 11(12): 750-761.
|
11. |
Gevers TJ, Drenth JP. Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol, 2013, 10(2): 101-108.
|
12. |
Abu-Wasel B, Walsh C, Keough V, et al. Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases. World J Gastroenterol, 2013, 19(35): 5775-5786.
|
13. |
Cnossen WR, Drenth JP. Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management. Orphanet J Rare Dis, 2014, 9: 69. doi: 10.1186/1750-1172-9-69.
|
14. |
van Keimpema L, De Koning DB, Van Hoek B, et al. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int, 2011, 31(1): 92-98.
|
15. |
Chandok N. Polycystic liver disease: a clinical review. Ann Hepatol, 2012, 11(6): 819-826.
|
16. |
Wong MY, McCaughan GW, Strasser SI. An update on the pathophysiology and management of polycystic liver disease. Expert Rev Gastroenterol Hepatol, 2017, 11(6): 569-581.
|
17. |
Kim H, Park HC, Ryu H, et al. Clinical correlates of mass effect in autosomal dominant polycystic kidney disease. PLoS One, 2015, 10(12): e0144526. doi: 10.1371/journal. pone.0144526.
|
18. |
Temmerman F, Dobbels F, Ho TA, et al. Development and validation of a polycystic liver disease complaint-specific assessment (POLCA). J Hepatol, 2014, 61(5): 1143-1150.
|
19. |
Neijenhuis MK, Gevers TJ, Hogan MC, et al. Development and validation of a disease-specific questionnaire to assess patient-reported symptoms in polycystic liver disease. Hepatology, 2016, 64(1): 151-160.
|
20. |
Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) Controversies Conference. Kidney Int, 2015, 88(1): 17-27.
|
21. |
Bakoyiannis A, Delis S, Triantopoulou C, et al. Rare cystic liver lesions: a diagnostic and managing challenge. World J Gastroenterol, 2013, 19(43): 7603-7619.
|
22. |
Temmerman F, Missiaen L, Bammens B, et al. Systematic review: the pathophysiology and management of polycystic liver disease. Aliment Pharmacol Ther, 2011, 34(7): 702-713.
|
23. |
Drenth JP, Chrispijn M, Nagorney DM, et al. Medical and surgical treatment options for polycystic liver disease. Hepatology, 2010, 52(6): 2223-2230.
|
24. |
Chauveau D, Fakhouri F, Grünfeld JP. Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. J Am Soc Nephrol, 2000, 11(9): 1767-1775.
|
25. |
Russell RT, Pinson CW. Surgical management of polycystic liver disease. World J Gastroenterol, 2007, 13(38): 5052-5059.
|
26. |
van Keimpema L, Ruurda JP, Ernst MF, et al. Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5%. J Gastrointest Surg, 2008, 12(3): 477-482.
|
27. |
Gigot JF, Jadoul P, Que F, et al. Adult polycystic liver disease: is fenestration the most adequate operation for long-term management? Ann Surg, 1997, 225(3): 286-294.
|
28. |
Schnelldorfer T, Torres VE, Zakaria S, et al. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg, 2009, 250(1): 112-118.
|
29. |
Bernts LHP, Neijenhuis MK, Edwards ME, et al. Symptom relief and quality of life after combined partial hepatectomy and cyst fenestration in highly symptomatic polycystic liver disease. Surgery, 2020, 168(1): 25-32.
|
30. |
Kirchner GI, Rifai K, Cantz T, et al. Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transpl, 2006, 12(8): 1268-1277.
|
31. |
Masyuk TV, Masyuk AI, LaRusso NF. Therapeutic targets in polycystic liver disease. Curr Drug Targets, 2017, 18(8): 950-957.
|
32. |
Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol, 2010, 21(6): 1052-1061.
|
33. |
van Keimpema L, Nevens F, Vanslembrouck R, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology, 2009, 137(5): 1661-1668.
|
34. |
Hogan MC, Masyuk TV, Page L, et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant, 2012, 27(9): 3532-3539.
|
35. |
Griffiths J, Mills MT, Ong AC. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis. BMJ Open, 2020, 10(1): e032620. doi: 10.1136/bmjopen-2019-032620.
|
36. |
Khan S, Dennison A, Garcea G. Medical therapy for polycystic liver disease. Ann R Coll Surg Engl, 2016, 98(1): 18-23.
|
37. |
Gevers TJ, Inthout J, Caroli A, et al. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology, 2013, 145(2): 357-365.
|
38. |
Aussilhou B, Dokmak S, Dondero F, et al. Treatment of polycystic liver disease. Update on the management. J Visc Surg, 2018, 155(6): 471-481.
|
39. |
Chrispijn M, Gevers TJ, Hol JC, et al. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. J Hepatol, 2013, 59(1): 153-159.
|
40. |
Deutschmann K, Reich M, Klindt C, et al. Bile acid receptors in the biliary tree: TGR5 in physiology and disease. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B): 1319-1325.
|
41. |
Barten TRM, Bernts LHP, Drenth JPH, et al. New insights into targeting hepatic cystogenesis in autosomal dominant polycystic liver and kidney disease. Expert Opin Ther Targets, 2020, 24(6): 589-599.
|